Although the DNA methylation biomarkers we discovered were not clinically validated, which could preclude their implementation in clinical practice, in silico validation revealed important aberrantly methylated genes including NPBWR1, CDH12, NR5A2, DCLK1, NKX2-2, KIAA1026, ADARB2, MAGI2, SMAD3, GUCY1B3, DOK6, EFS and PCSK2 implicated in CRC [32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55], suggesting that if further confirmed these genes could serve as prognostic markers. This evidence concerns the gene MAGI2 and colorectal carcinoma.